Frontiers in Immunology · 2023 · 34 citations · 21 references
MedicineGynecologyOncologyCancer ImmunologyGynecologic OncologyInflammationCancer BiomarkersCancer Survival AnalysisImmuno-oncology BiomarkersInflammatory BiomarkersOvarian CancerImmune Biomarkers In CancerNeutrophil-to-lymphocyte RatioOvarian Cancer BiomarkersOvarian Cancer Prognostic BiomarkersPlatelet-to-lymphocyte RatioPrognostic Inflammatory BiomarkersRelapse-free SurvivalSystemic Inflammation Markers
Background: Previous studies have suggested that the ratios of immune-inflammatory cells could serve as prognostic indicators in ovarian cancer. However, which of these is the superior prognostic indicator in ovarian cancer remains unknown. In addition, studies on the prognostic value of the platelet to neutrophil ratio (PNR) in ovarian cancer are still limited. Methods: A cohort of 991 ovarian cancer patients was analyzed in the present study. Receiver operator characteristic (ROC) curves were utilized to choose the optimal cut-off values of inflammatory biomarkers such as neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and PNR. The correlation of inflammatory biomarkers with overall survival (OS) and relapse-free survival (RFS) was investigated by Kaplan-Meier methods and log-rank test, followed by Cox regression analyses. Results: Kaplan-Meier curves suggested that LMR<3.39, PLR≥181.46, and PNR≥49.20 had obvious associations with worse RFS (P<0.001, P=0.018, P<0.001). Multivariate analysis suggested that LMR (≥3.39 vs. <3.39) (P=0.042, HR=0.810, 95% CI=0.661-0.992) and PNR (≥49.20 vs. <49.20) (P=0.004, HR=1.351, 95% CI=1.103-1.656) were independent prognostic indicators of poor RFS. In addition, Kaplan-Meier curves indicated that PLR≥182.23 was significantly correlated with worse OS (P=0.039). Conclusion: Taken together, PNR and LMR are superior prognostic indicators compared with NLR, PLR, and SII in patients with ovarian cancer.
21
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Willemien J. van Driel, Simone N. Koole, Karolina Sikorska et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text
Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin et al. · Annals of Oncology · 2019 · 840 citations · Full text
Medicine, Oncology, Pharmacology +15
Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung
Zvi Granot, Erik Henke, Elizabeth Comen et al. · Cancer Cell · 2011 · 783 citations · Full text
Medicine, Cancer Biology, Oncology +14
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
Mary L. Disis, Matthew H. Taylor, Karen Kelly et al. · JAMA Oncology · 2019 · 427 citations · Full text
Medicine, Oncology, Pharmacology +15